The effect of chloroquine treatment in malignant astrocytomas on prognosis

Basit Öğe Kaydı
dc.contributor.authorBulut, Turgay
dc.contributor.authorEkici, Mehmet Ali
dc.contributor.authorTucer, Bülent
dc.contributor.authorBaşarslan, Seyit Kaan
dc.contributor.authorKamaşak, Kağan
dc.contributor.authorKurtsoy, Ali
dc.date.accessioned2019-07-16T15:55:15Z
dc.date.available2019-07-16T15:55:15Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim: To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs). Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine treatment was started on a daily dose of 150 mg, additional to the patients’ radiotherapy and chemotherapy protocol, and was continued throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy. Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout the observation period and their mean survival time was 17 months. There were no statistical differences between the control and chloroquine groups (P > 0.05). Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAsen_US
dc.description.abstractAim: To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs). Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine treatment was started on a daily dose of 150 mg, additional to the patients’ radiotherapy and chemotherapy protocol, and was continued throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy. Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout the observation period and their mean survival time was 17 months. There were no statistical differences between the control and chloroquine groups (P > 0.05). Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAsen_US
dc.identifier.endpage789en_US
dc.identifier.issn1300-0144
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-84883032030en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage782en_US
dc.identifier.urihttps://trdizin.gov.tr/publication/paper/detail/TWpFeE56QXlNZz09
dc.identifier.urihttps://hdl.handle.net/20.500.12483/2015
dc.identifier.volume43en_US
dc.identifier.wosWOS:000323610400018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titleThe effect of chloroquine treatment in malignant astrocytomas on prognosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bulut, Turgay 2013.pdf
Boyut:
109.52 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu